Menu Search & Directory

Research Innovation Group

The Research Innovation Group (RIG) manages the intellectual property portfolio and industry contracting activities for Saint Louis University.

RIG’s mission is to increase the adoption and dissemination of SLU research discoveries and intellectual properties and to leverage SLU research and innovation assets to benefit the community. Our goal is to become exceptional at technology transfer and industry engagement as well as a partner of choice for research and intellectual property commercialization.

RIG’s main office is located in the heart of the Cortex Innovation Community to better connect with industry and integrate SLU within the region’s innovation and entrepreneurship ecosystem. The Cortex Innovation Community was founded in 2002 through a collaboration among SLU, Washington University in Saint Louis, University of Missouri – St. Louis, BJC Healthcare, and the Missouri Botanical Garden. It is the Midwest’s premier innovation hub for research, development, and commercialization in biosciences and technology. Cortex anchors the St. Louis region’s growing innovation ecosystem for startups and established companies.

For SLU Students

The Research Innovation Group at Saint Louis University offers support and encouragement to student entrepreneurship, innovation, and research excellence in a variety of ways. All current students are very welcome to contact us if you have any questions.


MEDLaunch is a non-profit biomedical and entrepreneurship incubator partnering with Saint Louis University and other organizations in the Saint Louis area. The goal of MedLaunch is to improve the standard of healthcare through the engineering and design of creative solutions while also fostering a community of entrepreneurship and collaboration at Saint Louis University.

Visit the MedLaunch Website

For Community Stakeholders

The Research Innovation Group at Saint Louis University is committed to leveraging our research and innovation assets for the benefit of our community. We strive to generate real impact in tackling social and scientific challenges facing our society through partnerships and programs.

The September 2017 Reinventing Research Commercialization Conference

The Research Innovation Group is committed to developing and implementing new approaches to technology transfer. It knows these will be needed to bring transformative discoveries resulting from university research more quickly and effectively to market. To this end, in September 2017, the Research Innovation Group brought together national leaders in technology transfer, regional innovators, entrepreneurs, business managers and advisors at the "Reinventing Research Commercialization Conference" to participate in this reinvention process.

The presentations from this conference are available below.


Technology Transfer Fellows Program

The Technology Transfer Fellows Program aims to help individuals develop translational research and lean innovation skills through experiential learning; expose individuals, particularly those from underrepresented groups, to the field of technology transfer; and facilitate the dissemination and adoption of Saint Louis University research discoveries and technologies.  

Participants in the program can earn an award up to $1,000 per project while working to advance the transfer of Saint Louis University technologies to the private sector to benefit the public interest. 

Individuals interested in participating in the Technology Transfer Fellows Program may apply online at any time.  The program is operated by the Research Innovation Group within the Office of the Vice President for Research at Saint Louis University.  Please contact Malcolm Townes by phone at 314-977-1633 or by email at if you have any questions.

Apply Now

Who can participate in the Technology Transfer Fellows Program? 

Anyone who meets the following requirements can participate in the Technology Transfer Fellows Program:

  • Individuals at least 18 years of age.
  • Eligible to work in the United States (if not a student or employee of Saint Louis University).

Participation in the program is at the sole and absolute discretion of Saint Louis University.  In addition to faculty, staff, postdoctoral researchers, graduate students, and undergraduate students at Saint Louis University, non-SLU affiliated individuals may also participate in the program. 
Participation in the Technology Transfer Fellows Program is not meant to replace a person's current employment.  Individuals are expected to participate in the program in adjunct to their normal jobs. 

How do I apply?
To apply, simply submit the online application.
Can individuals outside of the St. Louis, Missouri area participate in the program? 
Yes, individuals outside of the St. Louis, Missouri area are welcomed to participate in the program. 
What do participants in the Technology Transfer Fellows Program do? 

Technology Transfer Fellows participate in the SLUStart I-Corps program to advance the transfer of specific Saint Louis University technologies to the private sector to benefit the public interest.  This includes completing at least 10 customer discovery interviews and documenting a venture thesis for a technology. The primary tasks are as follows: 

  • Task 1: Participate in an initial SLUStart I-Corps cohort working session.
  • Task 2: Participate in a second SLUStart I-Corps cohort working session. 
  • Task 3: Prepare a plan for recruiting individuals for customer discovery interviews. 

    - For enterprise applications, provide a profile of the target user and a preliminary list of appropriate individuals (including job titles, company affiliation, and contact information) that the participant will approach for customer discovery interviews.

    - For consumer applications, provide a profile of the target user and a summary of the approach for contacting individuals in the target segment. 
  • Task 4: Complete and document the first five (5) customer discovery interviews according to program standards.
  • Task 5: Complete and document the next five (5) customer discovery interviews according to program standards and submit a venture thesis. 

 For individuals who are outside of the St. Louis, Missouri area, we can make special arrangements if necessary to facilitate their participation in the SLUStart I-Corps cohort sessions (i.e., Task 1 and Task 2). 

What technologies can Fellows work on for their project?

With approval from the program manager, Technology Transfer Fellows can work on any technology for which Saint Louis University has received an intellectual property disclosure that is not less than 60 days old, has accepted assignment of the technology, and is actively pursuing commercialization.

Are Fellows allowed to work on more than one project? 

Fellows may work on multiple projects during their participation only if invited to do so.  However, they may only work on one project at a time.  Once a participant completes a project, the program manager will evaluate the participants work and deliverables.  If the deliverables are satisfactory, the program manager may invite the fellow to perform additional work on the project or work on a different project. 

Do Fellows work on projects individually or in teams? 

Fellows may work on projects either individually or in teams of two with the approval of the program manager. 

How does the award work? 

Technology Transfer Fellows earn an award up to $1,000 per project.  The award is per individual.  Each fellow working on a project as a part of a team may earn an award up to $1,000 for achieving project milestones.  The award accrues based on project milestone attainment.  The current award accrual schedule per project is as follows: 

  • Deliverable 1: Documentation of participation in the first SLUStart I-Corps cohort session: $100.00
  • Deliverable 2: Documentation of participation in a second SLUStart I-Corps cohort session: $100.00
  • Deliverable 3: Documentation of a plan for recruiting individuals for customer discovery interviews according to program standards: $150.00 

    - For enterprise applications, provide a profile of the target user and a preliminary list of individuals (including job titles, company affiliation, email, and telephone number) that the participant will approach for customer discovery interviews.

    - For consumer applications, provide a profile of the target user and a summary of the approach for contacting individuals in the target segment.
  • Deliverable 4: Documentation of the first five (5) customer discovery interviews and an initial venture thesis statement according to program standards: $325.00
  • Deliverable 5: Documentation of the next five (5) customer discovery interviews and venture thesis statement according to program standards : $325.00 

Fellows have a limited amount of time to complete a project (typically about 2 months).  Awards payments are distributed after completion of all deliverables or expiration of the time allotted for the project, whichever occurs first. 

What time commitment is required to participate in the program? 

The two working sessions (i.e., SLUStart I-Corps cohort sessions) typically last about three (3) to four (4) hours each. The meeting days and times for the cohort working sessions are scheduled according the availability of the cohort participants.  In many cases, cohort sessions are scheduled on weekends or weekday evenings for the convenience of participants.  
Additionally, Fellows are expected to spend time outside of the working sessions applying what they've learned to conduct customer discovery interviews for their assigned SLU technologies.  However, exactly how much time a participant spends outside of the working sessions is at their discretion and will vary from project to project. The amount of time it takes to conduct each customer discovery interview is typically about 30 minutes but this varies to some degree.  This does not include the time required to recruit and schedule an interview participant.

What is a venture thesis? 
A venture thesis is simply a concise statement outlining the value that a technology or new venture is believed to offer to a specific customer segment or user population.  It has a specific structure designed to capture essential information about the technology application or solution, customer segment or user population, job-to-be-done from the perspective of the customer or user, and value proposition.  To see an example of a venture thesis, visit
Can Fellows continue to pursue commercialization of a technology on their own once they've completed their project? 
If a Fellow decides that they want to continue pursuing commercialization of the technology on their own once they've completed their project, they are welcomed to negotiate a license for the technology. 


Search Intellectual Property Portfolio

Use the directory below to browse and search our intellectual property portfolio to identify technologies that may be of interest to you.

ID Intellectual Property Type
ID Intellectual Property Type
98-013 NK3.3 Human Natural Killer Cell Line Derived from Healthy Male Research Tool
03-016 Studying Oncolytic Adenovirus Vectors Using a Syrian Hamster Model Research Tool
03-017 Studying Oncolytic Adenovirus Vectors Using a Cotton Rat Model Research Tool
06-013 Treating Metabolic Disorders in a Fetus Therapeutic
06-047 Treating Immune System Mediated Diseases Using TAT-BH3 Therapeutic
07-023 Minimizing Risks and Complications Associated with Retinal Detachment Surgery Medical Device
10-001 Improving Weather-Influenced Decisions Using Environmental Predictive Analytics Industrial Application
10-010 Developing an Antiviral Vaccine for Herpes Simplex Virus by Encoding Co-stimulation Molecules Therapeutic
10-014 Improving Robotic Systems for Brain Surgery Using a Self-Opening Distractor Medical Device
10-015 Improving Operating Room Procedures Using a Finger-based Data Input Device Medical Device
10-017 Detecting DNA and RNA Using Biolayer Interferometry with Ultra-High Sensitivity Diagnostic
10-018 Preventing and Treating Influenza Using Peptides to Induce Heterosubtypic Influenza T Cell Responses Therapeutic
10-019 Assessing the Language Proficiency of Individuals Using Crowdsourced Examinations Industrial Application
11-010 Studying Chronic Liver Disease Using a PiZ Transgenic Mouse Model of a1At Mutant Z Liver Injury Research Tool
11-013 Testing for Inherited Metabolic Diseases Diagnostic
11-015 Novel Approach for Treating Cancer Using Adenovirus E1A Fragments Drug Delivery
11-027 Treating Cornelia de Lange Syndrome Using Indomethacin-based Drugs Therapeutic
12-013 Preventing Bone Loss by Regulating FOXP3+CD8 T Cells Therapeutic
12-014 Treating Malaria Using Aminohydantoin Compounds Therapeutic
13-014 Microfluidic Device Systems and Methods for Fabrication Industrial Application
13-020 Treating Chronic Neuropathic Pain Using Phenotypic Screening Therapeutic
14-013 Delivering Bioactive Components Using a Hydrolytically Degradable Polyethylene Glycol Microsphere Drug Delivery
14-017 Diagnosing and Treating Endometriosis-related Infertility Therapeutic
14-018 Novel Therapeutic Strategy for Treating Human Breast Cancer Regulating SALL1 Functions Therapeutic
15-012 Producting Biomaterial Platforms for Researching Cell Substrate Relationships Industrial Application
15-014 Treating Cancers, Neurodegenerative Diseases, and Other Rare Conditions Using MUB LBL and LBL-based Peptides Drug Delivery
15-015 Suppressing Tumors Using MCPIP1 Therapeutic
15-026 Improve Tissue Healing Using a Honey-eluting Cryogel for Tissue Engineering Drug Delivery
15-027 Producing a Biocompatible and Biodegradable Silk Fibroin Cryogel for Use in Tissue Engineering Drug Delivery
15-032 Promoting Nerve Repair Using Neural Tissue Engineering Method of Transferring Single-Walled Carbon Nanotubes on a Hydrogel Drug Delivery
16-006 Integrating 3-Dimensional Cell Culture Scaffolds in Microfluidic Devices Industrial Application
16-011 Preventing and Treating Infections Caused by Herpesviridae Using Mutant Herpes Simplex Virus Therapeutic
16-018 Producing Nanomaterials Using Mask-free Production Methods Industrial Application
16-025 Blue Fluorescent Molecules for Organic Light Emitting Diodes Industrial Application
17-002 Novel Antibiotic Candidates Based on Inhibitors of Nucleotidyltransferase Superfamily Enzymes Therapeutic
17-003 Deriving Photoinduced Ring Closure From Dinaphthothiphenes Industrial Application
17-004 Treating Cancers and Infectious Diseases Using NK3.3-Derived Extracellular Vesicles Therapeutic
17-007 Measuring GPER Agonism, Antagonism, and Inverse Agonism Using a Novel High-Throughput Screening Assay Diagnostic
17-008 Maintaining GALNS Enzyme Activity for Extended Periods Using an Injectable Hydrogel Depot Drug Delivery
17-010 Regenerating Tissue Using an Aligned Electrospun Matrix of Decellularized Muscle Therapeutic
17-013 Treating Atherosclerosis by Induction of TcREG Therapeutic
17-015 Treating Short Gut Syndrome and Preventing Necrotizing Enterocolitis Using Fatty Acid Conjugated Epidermal Growth Factor Variants Therapeutic
17-017 Treating Facioscapulohumeral Muscular Dystrophy (FSHD) Using P38 Inhibitors Therapeutic
17-018 Minimizing the Collection Time for Hematopoietic Stem Cells Using Novel VLA4 Antagonist Compounds Drug Delivery
17-019 Minimizing the Collection Time for Hematopoietic Stem Cells Using Novel VLA4 Antagonist Compounds Drug Delivery
17-024 Measuring the Efficiency of Efflux Pumps in Bacterial Strains and Permeability Properties of Bacterial Cell Envelopes Using a Molecular Fluorescent Ruler Diagnostic
17-025 Repairing and Regenerating Tissue Using Biomimetic Sponges Therapeutic
17-026 Treating Muscle Dysfunction Using ERR Ligands Therapeutic
17-033 Treating Malaria Using Pyrrolidine Compounds Therapeutic
17-034 Assessing Biofilm Infections Using a Novel Bacterial Biofilm Assay Diagnostic
17-036 Treating Malaria Using Pyrrolidine Compounds Therapeutic
17-037 Dibenzothiophene Sulfone Cell Dyes Research Tool
17-038 Detecting Hemoglobin C in Environments that Lack Modern Infrastructure Using a Method Based on Induction of Intracellular HbC Crystals Diagnostic
17-039 Treating Cancer Using Novel Molecules for Photodynamic Therapy Drug Delivery
17-040 Improving Cognitive Function in Aging-related Dementia Using Adropun Peptides Therapeutic
17-041 Treating Atherosclerosis by Induction of Regulatory CD8T Cells Therapeutic
18-003 Treating Cancer Using Synthesis of a Molecule that Undergoes S-O Bond Cleavage to Produce a Toxic Compound Therapeutic
18-006 Performing Multiple PCR-based Laboratory Developed Tests Simultaneously Using a Common PCR Platform System Research Tool
18-010 Studying the Role of GPER in Various Diseases Using Novel GPER Agonists Research Tool
18-012 Developing Better Treatments for Resistant Cancers Using Novel Small Molecule Inhibitors of the Human RECQ1 Helicase Drug Delivery
18-013 Eliminating Bacterial Biofilms Using a Phytochemical Therapeutic
18-017 Treating Facioscapulohumeral Muscular Dystrophy (FSHD) Using P38 Beta-selective Inhibitors Therapeutic
18-018 Developing Treatments for Hematological Disorders Caused by B19V Infection Using Small Molecule Compounds That Directly Inhibit B19V Replication Drug Delivery
18-020 Treating Zika Virus Using Selective Estrogen Modulators Therapeutic
18-023 Treating Facioscapulohumeral Muscular Dystrophy (FSHD) Using Pyrrolopyridinone Compounds that Inhibit BET Bromodomains Therapeutic
18-024 Improving the Consistency of Image-guided Head and Neck Radiotherapy Delivery Using an Auto-adaptable Head Rest Medical Device
18-026 Generating Atomic Oxygen Using Visible Light Drug Delivery
18-027 Treating Hepatitis B Virus Infection Using Alpha-Hydroxytropolones as Inhibitors of HBV Replication Therapeutic
18-028 Improving Large-Scale Study of Proteins Using Mass Spectroscopy with Isotope Labeling Research Tool
19-001 Creating New Fluorescent Microscopy Plasma Membrane Dyes Using DBTOO Analogs Research Tool
19-006 Automating the Analysis of Chimerism Data Research Tool
19-007 Detecting Exposure to Specific Pathogens and Agents Diagnostic
19-008 Minimizing Epidural Catheter Migration Medical Device
19-009 Treating Fungal Infections in HIV-positive Patients and Solid Organ Transplant Recipients Therapeutic
19-010 Improving Tumor Immunotherapy by Reprogramming Lipid Metabolism Therapeutic
19-011 Delivering Medicines in a Controlled Manner Over an Extended Period of Time Using Degradable Hydrogels Drug Delivery
19-012 Custom Plasmids for Expressing Nuclear Receptor Proteins in E. Coli and Optimized Protocols for Protein Expression and Purification Therapeutic
19-013 Introducing Tangible Interactions into Existing Telepresence and Telerobotics Systems Medical Device
19-014 Using GCNF Ligands to Increase the Efficacy of Cancer Therapeutics Therapeutic
19-015 Using a Novel Mechanism to Treat MRSA Infections and Tuberculosis Therapeutic
19-016 Video and Microphone Enabled Keypad for Use in Healthcare Systems Medical Device
19-017 Improving Telepathology Medical Device
19-018 Locating and Quantifying Off-Target Embolization Diagnostic
19-019 Treating and Preventing Neuropathic Pain Using Novel Non-Narcotic Analgesics Therapeutic
19-020 Treating Neurological Diseases, Autoimmune Disorders, and Muscular Disorders Using Rev-erb Modulators Therapeutic
19-021 Improving the X-Ray Imaging of the Vasculature of Biological Systems Diagnostic
19-022 Improving Tissue Engineering Scaffolds for Wound Healing Using Metallic Nanoparticles Medical Device
19-024 Simplifying Polyaxial Screw Insertion During Robotic Spinal Surgery Medical Device
19-025 Preventing Herpes Simplex Virus Replication with a New Class of Drugs that Act by a Novel Mechanism Therapeutic
19-027 Treating Frontotemporal Dementia Therapeutic
19-028 Improving DNA Sequencing Diagnostics
19-029 Treating Traumatic Brain Injuries Therapeutic